Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
The advanced algorithm achieved a sensitivity of 93% and specificity of 98%. It was trained to identify up to five different valvular diseases at the same time from a single audio clip.
Preventing sudden cardiac arrest involves managing risk factors such as hypertension, hyperlipidemia and diabetes. We spoke to Christine Albert, MD, about this and much more at ESC 2023.
When combined with a good microphone, "positive findings only" radiology reporting utilizing voice commands may be most efficient style, according to new research.
Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
